NCT00842361View on ClinicalTrials.gov

Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

insulin degludec/insulin aspart

The insulin NN5401 (insulin degludec/insulin aspart) injected subcutaneously immediately before breakfast and dinner.

DRUG

biphasic insulin aspart 30

The insulin (biphasic insulin aspart 30) injected subcutaneously immediately before breakfast and dinner.

Trial Locations (8)

103 0002

Novo Nordisk Investigational Site, Chuo-ku, Tokyo

880 0034

Novo Nordisk Investigational Site, Miyazaki

311 0113

Novo Nordisk Investigational Site, Naka-shi, Ibaraki

144 0035

Novo Nordisk Investigational Site, Ota-ku, Tokyo

323 0022

Novo Nordisk Investigational Site, Oyama-shi, Tochigi

980 0021

Novo Nordisk Investigational Site, Sendai

424 0853

Novo Nordisk Investigational Site, Shizuoka

985 0852

Novo Nordisk Investigational Site, Tagajō-shi

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT00842361 - Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter